Classification: Enzyme, miscellaneous
Action/Kinetics: Hydrolyzes hyaluronic acid, a constituent of connective tissue, which promotes the diffusion of injected liquids. The purified enzyme has no effect on BP, respiration, temperature, and kidney function. It is antigenic and repeated use may induce the formation of antibodies that neutralize the effect. Local infection will not spread as long as it is not injected into the infected area. Duration: 24-48 hr.
Uses: Adjunct to promote absorption and dispersion of liquids and drugs, for hypodermoclysis, adjunct in urography to improve resorption of radiopaque agents, administration of local anesthetics. (Hyaluronidase can be added to primary drug solution or injected prior to administration of primary drug solution.)
Contraindications: Do not inject into acutely infected or cancerous areas.
Special Concerns: Use with caution during lactation.
Side Effects: Rarely, sensitivity reactions, including urticaria and anaphylaxis.
Overdose Management: Symptoms: Local edema or urticaria, chills, erythema, dizziness, N&V, tachycardia, hypotension. Treatment: Discontinue and begin supportive treatment immediately. Epinephrine, corticosteroids, and antihistamines may be required to treat symptoms.
How Supplied: Injection: 150 U/mL; Powder for injection: 150 U, 1,500 U
Dosage •SC Drug and fluid dispersion. Adults and older children, usual: 150 units added to the injection solution. SC urography. (When IV injection cannot be used.) With client in prone position: 75 units SC over each scapula, followed by contrast medium in same site. Hypodermoclysis. 150 units, which facilitates absorption of 1,000 mL fluid (give at a rate no faster than would be used for IV infusion); pediatric, less than 3 years: volume of single clysis should be limited to 200 mL; premature infants, neonates: do not exceed 25 mL/kg/day given at a rate no greater than 2 mL/min.